The cost-effectiveness of influenza vaccination for people aged 50 to 64 years: an international model.
Identifieur interne : 000470 ( Main/Corpus ); précédent : 000469; suivant : 000471The cost-effectiveness of influenza vaccination for people aged 50 to 64 years: an international model.
Auteurs : Samuel Aballéa ; Jeremy Chancellor ; Monique Martin ; Peter Wutzler ; Fabrice Carrat ; Roberto Gasparini ; Joao Toniolo-Neto ; Michael Drummond ; Milton WeinsteinSource :
- Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research [ 1098-3015 ]
English descriptors
- KwdEn :
- Age Factors, Brazil (epidemiology), Cost-Benefit Analysis, Decision Support Techniques, Female, France (epidemiology), Germany (epidemiology), Health Policy (economics), Humans, Immunization Programs (economics), Influenza Vaccines (administration & dosage), Influenza Vaccines (economics), Influenza, Human (economics), Influenza, Human (epidemiology), Influenza, Human (prevention & control), Internationality, Italy (epidemiology), Life Expectancy, Male, Middle Aged, Models, Econometric, Quality-Adjusted Life Years.
- MESH :
- chemical , administration & dosage : Influenza Vaccines.
- chemical , economics : Influenza Vaccines.
- geographic , epidemiology : Brazil, France, Germany, Italy.
- economics : Health Policy, Immunization Programs, Influenza, Human.
- epidemiology : Influenza, Human.
- prevention & control : Influenza, Human.
- Age Factors, Cost-Benefit Analysis, Decision Support Techniques, Female, Humans, Internationality, Life Expectancy, Male, Middle Aged, Models, Econometric, Quality-Adjusted Life Years.
Abstract
Routine influenza vaccination is currently recommended in several countries for people aged more than 60 or 65 years or with high risk of complications. A lower age threshold of 50 years has been recommended in the United States since 1999. To help policymakers consider whether such a policy should be adopted more widely, we conducted an economic evaluation of lowering the age limit for routine influenza vaccination to 50 years in Brazil, France, Germany, and Italy.
DOI: 10.1111/j.1524-4733.2006.00157.x
PubMed: 17391419
Links to Exploration step
pubmed:17391419Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The cost-effectiveness of influenza vaccination for people aged 50 to 64 years: an international model.</title>
<author><name sortKey="Aballea, Samuel" sort="Aballea, Samuel" uniqKey="Aballea S" first="Samuel" last="Aballéa">Samuel Aballéa</name>
<affiliation><nlm:affiliation>i3 Innovus, Uxbridge, UK.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Chancellor, Jeremy" sort="Chancellor, Jeremy" uniqKey="Chancellor J" first="Jeremy" last="Chancellor">Jeremy Chancellor</name>
</author>
<author><name sortKey="Martin, Monique" sort="Martin, Monique" uniqKey="Martin M" first="Monique" last="Martin">Monique Martin</name>
</author>
<author><name sortKey="Wutzler, Peter" sort="Wutzler, Peter" uniqKey="Wutzler P" first="Peter" last="Wutzler">Peter Wutzler</name>
</author>
<author><name sortKey="Carrat, Fabrice" sort="Carrat, Fabrice" uniqKey="Carrat F" first="Fabrice" last="Carrat">Fabrice Carrat</name>
</author>
<author><name sortKey="Gasparini, Roberto" sort="Gasparini, Roberto" uniqKey="Gasparini R" first="Roberto" last="Gasparini">Roberto Gasparini</name>
</author>
<author><name sortKey="Toniolo Neto, Joao" sort="Toniolo Neto, Joao" uniqKey="Toniolo Neto J" first="Joao" last="Toniolo-Neto">Joao Toniolo-Neto</name>
</author>
<author><name sortKey="Drummond, Michael" sort="Drummond, Michael" uniqKey="Drummond M" first="Michael" last="Drummond">Michael Drummond</name>
</author>
<author><name sortKey="Weinstein, Milton" sort="Weinstein, Milton" uniqKey="Weinstein M" first="Milton" last="Weinstein">Milton Weinstein</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="????"><PubDate><MedlineDate>2007 Mar-Apr</MedlineDate>
</PubDate>
</date>
<idno type="RBID">pubmed:17391419</idno>
<idno type="pmid">17391419</idno>
<idno type="doi">10.1111/j.1524-4733.2006.00157.x</idno>
<idno type="wicri:Area/Main/Corpus">000470</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000470</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">The cost-effectiveness of influenza vaccination for people aged 50 to 64 years: an international model.</title>
<author><name sortKey="Aballea, Samuel" sort="Aballea, Samuel" uniqKey="Aballea S" first="Samuel" last="Aballéa">Samuel Aballéa</name>
<affiliation><nlm:affiliation>i3 Innovus, Uxbridge, UK.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Chancellor, Jeremy" sort="Chancellor, Jeremy" uniqKey="Chancellor J" first="Jeremy" last="Chancellor">Jeremy Chancellor</name>
</author>
<author><name sortKey="Martin, Monique" sort="Martin, Monique" uniqKey="Martin M" first="Monique" last="Martin">Monique Martin</name>
</author>
<author><name sortKey="Wutzler, Peter" sort="Wutzler, Peter" uniqKey="Wutzler P" first="Peter" last="Wutzler">Peter Wutzler</name>
</author>
<author><name sortKey="Carrat, Fabrice" sort="Carrat, Fabrice" uniqKey="Carrat F" first="Fabrice" last="Carrat">Fabrice Carrat</name>
</author>
<author><name sortKey="Gasparini, Roberto" sort="Gasparini, Roberto" uniqKey="Gasparini R" first="Roberto" last="Gasparini">Roberto Gasparini</name>
</author>
<author><name sortKey="Toniolo Neto, Joao" sort="Toniolo Neto, Joao" uniqKey="Toniolo Neto J" first="Joao" last="Toniolo-Neto">Joao Toniolo-Neto</name>
</author>
<author><name sortKey="Drummond, Michael" sort="Drummond, Michael" uniqKey="Drummond M" first="Michael" last="Drummond">Michael Drummond</name>
</author>
<author><name sortKey="Weinstein, Milton" sort="Weinstein, Milton" uniqKey="Weinstein M" first="Milton" last="Weinstein">Milton Weinstein</name>
</author>
</analytic>
<series><title level="j">Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research</title>
<idno type="ISSN">1098-3015</idno>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Age Factors</term>
<term>Brazil (epidemiology)</term>
<term>Cost-Benefit Analysis</term>
<term>Decision Support Techniques</term>
<term>Female</term>
<term>France (epidemiology)</term>
<term>Germany (epidemiology)</term>
<term>Health Policy (economics)</term>
<term>Humans</term>
<term>Immunization Programs (economics)</term>
<term>Influenza Vaccines (administration & dosage)</term>
<term>Influenza Vaccines (economics)</term>
<term>Influenza, Human (economics)</term>
<term>Influenza, Human (epidemiology)</term>
<term>Influenza, Human (prevention & control)</term>
<term>Internationality</term>
<term>Italy (epidemiology)</term>
<term>Life Expectancy</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Models, Econometric</term>
<term>Quality-Adjusted Life Years</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Influenza Vaccines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="economics" xml:lang="en"><term>Influenza Vaccines</term>
</keywords>
<keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Brazil</term>
<term>France</term>
<term>Germany</term>
<term>Italy</term>
</keywords>
<keywords scheme="MESH" qualifier="economics" xml:lang="en"><term>Health Policy</term>
<term>Immunization Programs</term>
<term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Age Factors</term>
<term>Cost-Benefit Analysis</term>
<term>Decision Support Techniques</term>
<term>Female</term>
<term>Humans</term>
<term>Internationality</term>
<term>Life Expectancy</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Models, Econometric</term>
<term>Quality-Adjusted Life Years</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Routine influenza vaccination is currently recommended in several countries for people aged more than 60 or 65 years or with high risk of complications. A lower age threshold of 50 years has been recommended in the United States since 1999. To help policymakers consider whether such a policy should be adopted more widely, we conducted an economic evaluation of lowering the age limit for routine influenza vaccination to 50 years in Brazil, France, Germany, and Italy.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17391419</PMID>
<DateCompleted><Year>2007</Year>
<Month>05</Month>
<Day>25</Day>
</DateCompleted>
<DateRevised><Year>2007</Year>
<Month>03</Month>
<Day>29</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">1098-3015</ISSN>
<JournalIssue CitedMedium="Print"><Volume>10</Volume>
<Issue>2</Issue>
<PubDate><MedlineDate>2007 Mar-Apr</MedlineDate>
</PubDate>
</JournalIssue>
<Title>Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research</Title>
<ISOAbbreviation>Value Health</ISOAbbreviation>
</Journal>
<ArticleTitle>The cost-effectiveness of influenza vaccination for people aged 50 to 64 years: an international model.</ArticleTitle>
<Pagination><MedlinePgn>98-116</MedlinePgn>
</Pagination>
<Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Routine influenza vaccination is currently recommended in several countries for people aged more than 60 or 65 years or with high risk of complications. A lower age threshold of 50 years has been recommended in the United States since 1999. To help policymakers consider whether such a policy should be adopted more widely, we conducted an economic evaluation of lowering the age limit for routine influenza vaccination to 50 years in Brazil, France, Germany, and Italy.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">The probabilistic model was designed to compare in a single season the costs and clinical outcomes associated with two alternative vaccination policies for persons aged 50 to 64 years: reimbursement only for people at high risk of complications (current policy), and reimbursement for all individuals in this age group (proposed policy). Two perspectives were considered: third-party payer (TPP) and societal. Model inputs were obtained primarily from the published literature and validated through expert opinion. The historical distribution of annual influenza-like illness (ILI) incidence was used to simulate the uncertain incidence in any given season. We estimated gains in unadjusted and quality-adjusted life expectancy, and the cost per quality-adjusted life-year (QALY) gained. Deterministic and probabilistic sensitivity analyses were conducted.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Comparing the proposed to the current policy, the estimated mean costs per QALY gained were R$4,100, EURO 13,200, EURO 31,400 and EURO 15,700 for Brazil, France, Germany, and Italy, respectively, from a TPP perspective. From the societal perspective, the age-based policy is predicted to yield net cost savings in Germany and Italy, whereas the cost per QALY decreased to R$2800 for Brazil and EURO 8000 for France. The results were particularly sensitive to the ILI incidence rate, vaccine uptake, influenza fatality rate, and the costs of administering vaccination. Assuming a cost-effectiveness threshold ratio of EURO 50,000 per QALY gained, the probabilities of the new policy being cost-effective were 94% and 95% for France, 72% and near 100% for Germany, and 89% and 99% for Italy, from the TPP and societal perspectives, respectively.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Extending routine influenza vaccination to people more than 50 years of age is likely to be cost-effective in all four countries studied.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Aballéa</LastName>
<ForeName>Samuel</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>i3 Innovus, Uxbridge, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Chancellor</LastName>
<ForeName>Jeremy</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y"><LastName>Martin</LastName>
<ForeName>Monique</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y"><LastName>Wutzler</LastName>
<ForeName>Peter</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y"><LastName>Carrat</LastName>
<ForeName>Fabrice</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="Y"><LastName>Gasparini</LastName>
<ForeName>Roberto</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y"><LastName>Toniolo-Neto</LastName>
<ForeName>Joao</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y"><LastName>Drummond</LastName>
<ForeName>Michael</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y"><LastName>Weinstein</LastName>
<ForeName>Milton</ForeName>
<Initials>M</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Value Health</MedlineTA>
<NlmUniqueID>100883818</NlmUniqueID>
<ISSNLinking>1098-3015</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001938" MajorTopicYN="N" Type="Geographic">Brazil</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003362" MajorTopicYN="N">Cost-Benefit Analysis</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003661" MajorTopicYN="N">Decision Support Techniques</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005602" MajorTopicYN="N" Type="Geographic">France</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N" Type="Geographic">Germany</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006291" MajorTopicYN="N">Health Policy</DescriptorName>
<QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017589" MajorTopicYN="N">Immunization Programs</DescriptorName>
<QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
<QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName>
<QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D038622" MajorTopicYN="N">Internationality</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007558" MajorTopicYN="N" Type="Geographic">Italy</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008017" MajorTopicYN="N">Life Expectancy</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017059" MajorTopicYN="N">Models, Econometric</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019057" MajorTopicYN="N">Quality-Adjusted Life Years</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year>
<Month>3</Month>
<Day>30</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2007</Year>
<Month>5</Month>
<Day>26</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2007</Year>
<Month>3</Month>
<Day>30</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">17391419</ArticleId>
<ArticleId IdType="pii">S1098-3015(10)60458-5</ArticleId>
<ArticleId IdType="doi">10.1111/j.1524-4733.2006.00157.x</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=ExplorPubmed/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000470 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000470 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= *** parameter Area/wikiCode missing *** |area= ExplorPubmed |flux= Main |étape= Corpus |type= RBID |clé= pubmed:17391419 |texte= The cost-effectiveness of influenza vaccination for people aged 50 to 64 years: an international model. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:17391419" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a ExplorPubmed
This area was generated with Dilib version V0.6.35. |